{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:47:59Z","timestamp":1762508879068},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,19]]},"DOI":"10.7759\/cureus.30480","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:23:57Z","timestamp":1666200237000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Encephalitis With an Unusual Frontomesial Motor Cortex T2 MRI Hyperintensity"],"prefix":"10.7759","author":[{"given":"Giulio","family":"Papiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Puca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Paci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000974","article-title":"Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis","volume":"8","author":"Mu\u00f1iz-Castrillo S","year":"2021","unstructured":"Mu\u00f1iz-Castrillo S, Haesebaert J, Thomas L, et al.. Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021, 8:3-7. 10.1212\/NXI.0000000000000974","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.791014","article-title":"Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis: a systematic review","volume":"12","author":"Teng Y","year":"2021","unstructured":"Teng Y, Li T, Yang Z, et al.. Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis: a systematic review. Front Neurol. 2021, 12:791014. 10.3389\/fneur.2021.791014","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17055","article-title":"Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features","volume":"62","author":"Suga H","year":"2021","unstructured":"Suga H, Yanagida A, Kanazawa N, et al.. Status epilepticus suspected autoimmune: Neuronal surface antibodies and main clinical features. Epilepsia. 2021, 62:2719-31. 10.1111\/epi.17055","journal-title":"Epilepsia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221089","article-title":"Anti-LGI1 encephalitis causing faciobrachial dystonic seizures","volume":"2017","author":"Zouras S","year":"2017","unstructured":"Zouras S, Stephens JW, Abburu SR, Emelle C. Anti-LGI1 encephalitis causing faciobrachial dystonic seizures. BMJ Case Rep. 2017, 2017:1-5. 10.1136\/bcr-2017-221089","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen A","year":"2016","unstructured":"van Sonderen A, Thijs RD, Coenders EC, et al.. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016, 87:1449-56. 10.1212\/WNL.0000000000003173","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10060375","article-title":"Psychiatric manifestation of anti-LGI1 encephalitis","volume":"10","author":"Endres D","year":"2020","unstructured":"Endres D, Pr\u00fcss H, Dressing A, et al.. Psychiatric manifestation of anti-LGI1 encephalitis. Brain Sci. 2020, 10:3-7. 10.3390\/brainsci10060375","journal-title":"Brain Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001136","article-title":"Cortical and subcortical dysmetabolism are dynamic markers of clinical disability and course in anti-LGI1 encephalitis","volume":"9","author":"Rissanen E","year":"2022","unstructured":"Rissanen E, Carter K, Cicero S, et al.. Cortical and subcortical dysmetabolism are dynamic markers of clinical disability and course in anti-LGI1 encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022, 9:1-5. 10.1212\/NXI.0000000000001136","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2019.247","article-title":"Anti-LGI1 limbic encephalitis presenting as an expanding insular lesion","volume":"46","author":"Bose G","year":"2019","unstructured":"Bose G, Zwicker JC, Sitwell LD, Osman N, Fantaneanu TA. Anti-LGI1 limbic encephalitis presenting as an expanding insular lesion. Can J Neurol Sci. 2019, 46:770-2. 10.1017\/cjn.2019.247","journal-title":"Can J Neurol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13707","article-title":"Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis","volume":"27","author":"Li TR","year":"2021","unstructured":"Li TR, Zhang YD, Wang Q, Shao XQ, Lv RJ. Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis. CNS Neurosci Ther. 2021, 27:1173-81. 10.1111\/cns.13707","journal-title":"CNS Neurosci Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15384","article-title":"Whole-brain metabolic pattern analysis in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis","volume":"29","author":"Mo J","year":"2022","unstructured":"Mo J, Dong W, Cui T, et al.. Whole-brain metabolic pattern analysis in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis. Eur J Neurol. 2022, 29:2376-85. 10.1111\/ene.15384","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772096","article-title":"Positive LGI1 antibodies in CSF and relapse relate to worse outcome in anti-LGI1 encephalitis","volume":"12","author":"Cui LL","year":"2021","unstructured":"Cui LL, Boltze J, Zhang Y. Positive LGI1 antibodies in CSF and relapse relate to worse outcome in anti-LGI1 encephalitis. Front Immunol. 2021, 12:772096. 10.3389\/fimmu.2021.772096","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1793","article-title":"Anti-LGI1, anti-GABABR, and anti-CASPR2 encephalitides in Asia: a systematic review","volume":"10","author":"Ghimire P","year":"2020","unstructured":"Ghimire P, Khanal UP, Gajurel BP, et al.. Anti-LGI1, anti-GABABR, and anti-CASPR2 encephalitides in Asia: a systematic review. Brain Behav. 2020, 10:e01793. 10.1002\/brb3.1793","journal-title":"Brain Behav"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00852","article-title":"Clinical characteristics of cognitive impairment and 1-year outcome in patients with anti-LGI1 antibody encephalitis","volume":"11","author":"Hang HL","year":"2020","unstructured":"Hang HL, Zhang JH, Chen DW, Lu J, Shi JP. Clinical characteristics of cognitive impairment and 1-year outcome in patients with anti-LGI1 antibody encephalitis. Front Neurol. 2020, 11:852. 10.3389\/fneur.2020.00852","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211073203","article-title":"Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1\/Caspr2 encephalitis: a prospective cohort study in Western China","volume":"15","author":"Guo K","year":"2022","unstructured":"Guo K, Liu X, Lin J, et al.. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1\/Caspr2 encephalitis: a prospective cohort study in Western China. Ther Adv Neurol Disord. 2022, 15:3203. 10.1177\/17562864211073203","journal-title":"Ther Adv Neurol Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus F","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, et al.. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016, 15:391-404. 10.1016\/S1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani SR","year":"2011","unstructured":"Irani SR, Michell AW, Lang B, et al.. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011, 69:892-900. 10.1002\/ana.22307","journal-title":"Ann Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/109671-a-case-of-anti-leucine-rich-glioma-inactivated-protein-1-anti-lgi1-encephalitis-with-an-unusual-frontomesial-motor-cortex-t2-mri-hyperintensity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:11Z","timestamp":1707508331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/109671-a-case-of-anti-leucine-rich-glioma-inactivated-protein-1-anti-lgi1-encephalitis-with-an-unusual-frontomesial-motor-cortex-t2-mri-hyperintensity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.30480","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}